US Broker Ratings

iRhythm Holdings, Inc. (IRTC) Stock Analysis: A 41% Potential Upside Beckons Investors

iRhythm Holdings, Inc. (NASDAQ: IRTC), a prominent player in the healthcare sector specializing in medical devices, presents an intriguing opportunity for investors as it navigates the dynamic landscape of digital..

Telix Pharmaceuticals Limited (TLX): Investor Outlook Unveils 75% Upside Potential

Telix Pharmaceuticals Limited (TLX), a burgeoning force in the biotechnology sector, is capturing investor attention with its promising growth trajectory and substantial upside potential. With a market capitalization of $4.02..

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 29.48% Potential Upside in the Biotech Sphere

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a prominent player in the biotechnology sector, is attracting investor attention with its potential upside of 29.48%. With a current stock price of $81.80, Ionis..

ADMA Biologics Inc (ADMA) Stock Analysis: High Potential Upside Amid Robust Growth Trends

ADMA Biologics Inc (NASDAQ: ADMA), a pioneering player in the biotechnology sector, is poised for substantial growth, offering a remarkable potential upside of 96.65%. This healthcare company, with a market..

TG Therapeutics, Inc. (TGTX) Investor Outlook: Navigating Growth with High Potential in Biotech

TG Therapeutics, Inc. (NASDAQ: TGTX), a key player in the biotechnology sector, stands out with its strategic focus on developing innovative treatments for B-cell mediated diseases. Headquartered in Morrisville, North..

Grifols, S.A. (GRFS) Stock Analysis: A 51.75% Upside Potential in the Healthcare Sector

Grifols, S.A. (NASDAQ: GRFS), a key player in the healthcare sector, is drawing attention from investors with its substantial potential upside of 51.75%, as indicated by the average target price..

Incyte Corporation (INCY) Stock Analysis: Navigating Growth with a Robust Pipeline and Strong Revenue Growth

For investors eyeing the healthcare sector, Incyte Corporation (NASDAQ: INCY) presents a compelling opportunity, primarily driven by its robust revenue growth and impressive return on equity. As a key player..

Guardant Health, Inc. (GH) Stock Analysis: A Promising Path in Precision Oncology Despite Financial Hurdles

Guardant Health, Inc. (NASDAQ: GH) is carving out a significant niche in the healthcare sector, specifically within diagnostics and research. Headquartered in Palo Alto, California, this precision oncology company has..

Oscar Health, Inc. (OSCR) Stock Analysis: Navigating Market Uncertainties with a Strong Revenue Growth

Oscar Health, Inc. (NYSE: OSCR), a forward-thinking healthcare technology company, is catching the attention of investors with its dynamic approach to health plans and technology solutions. Headquartered in New York,..

Prestige Consumer Healthcare (PBH) Stock Analysis: Understanding Its 35% Potential Upside

Prestige Consumer Healthcare Inc. (NYSE: PBH) presents an intriguing opportunity for investors seeking to capitalize on a niche player in the healthcare sector. With a market capitalization of $2.34 billion,..

Krystal Biotech, Inc. (KRYS) Stock Analysis: A High-Potential Biotech with Robust Revenue Growth and Strategic Therapeutic Pipeline

Krystal Biotech, Inc. (NASDAQ: KRYS) is making waves in the biotechnology sector with its impressive market cap of $11.06 billion. The company’s innovative approach to genetic medicines, particularly in addressing..

Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings and Promising 41.2% Revenue Growth Propel Market Confidence

Glaukos Corporation (NYSE: GKOS), a pivotal player in the healthcare sector specializing in medical devices, continues to capture investor attention with its robust growth prospects and innovative product lineup. As..

Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside

Neurocrine Biosciences, Inc. (NBIX), a prominent player in the healthcare sector, has captured investor attention with its robust growth prospects and a promising 12.47% potential upside based on analyst projections...

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is capturing investor attention with its promising position in the biotechnology sector. Specializing in the treatment of rare neuroendocrine diseases, Rhythm Pharmaceuticals is a commercial-stage..

Cytokinetics, Incorporated (CYTK)

⚠️ No article content returned.

..

Roivant Sciences Ltd. (ROIV) Stock Analysis: Potential Upside Amidst Biotech Innovations

Roivant Sciences Ltd. (NASDAQ: ROIV), a clinical-stage biopharmaceutical company headquartered in London, is making waves in the healthcare sector with its innovative approach to drug development. With a market capitalization..

Gilead Sciences, Inc. (GILD) Stock Analysis: Unlocking a 20% Potential Upside for Investors

Gilead Sciences, Inc. (NASDAQ: GILD), a titan in the healthcare sector, remains a compelling investment opportunity within the drug manufacturing industry. With a market capitalization of $162.98 billion, Gilead’s robust..

West Pharmaceutical Services, Inc. (WST): Analyst Consensus Highlights Growth Amidst a Robust Market Position

West Pharmaceutical Services, Inc. (NYSE: WST) is a formidable player in the healthcare sector, specifically within the medical instruments and supplies industry. With a substantial market capitalization of $25.84 billion,..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Unveiling Growth Potential in the Eye Health Sector

For investors looking to delve into the healthcare sector, Bausch + Lomb Corporation (NYSE: BLCO) presents a compelling opportunity. With a focus on eye health, the company is positioned in..

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 14.93% Potential Upside for Investors

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, continues to capture investor interest with its robust financial performance and strategic initiatives in the biopharmaceutical domain. As of the latest..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds